ArticleWorld journal of gastroenterology2019
Procyanidin B2 protects against diet-induced obesity and non-alcoholic fatty liver disease
Article in World journal of gastroenterology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 61 citations in OpenAlex.
- Akkermansia: A Potential Target for Natural Botanicals in Treatment of Nonalcoholic Fatty Liver Diseases.Chinese journal of integrative medicine · 2026Review
- Compositional Analysis of Polymeric Proanthocyanidins fromFoods (Basel, Switzerland) · 2026Article
- Review
- Complexation of Anthocyanin-Rich Blackberry Extract With Ozonated Sodium Alginate: Structural, Rheological, and Color Insights.Journal of food science · 2026Article
- Procyanidin B2 and an autochthonous apple pulp extract modulate oxidative stress and PPARγ expression on an in vitro model of lipid steatosis in HepG2 cells.Journal of physiology and biochemistry · 2026Article
- Procyanidin Suppresses Tumor Growth by Activating the B-Cell MAPK Pathway through Remodulation of the Gut Microbiota and Metabolites in Hepatocellular Carcinoma.International journal of biological sciences · 2026Article
- B-Type Trimeric Procyanidins Attenuate Nonalcoholic Hepatic Steatosis Through AMPK/mTOR Signaling Pathway in Oleic Acid-Induced HepG2 Cells and High-Fat Diet- Fed Zebrafish.Plant foods for human nutrition (Dordrecht, Netherlands) · 2025Article
- In vivo Differential Effects of Extractable and Non-Extractable Phenolic Compounds from Grape Pomace on the Regulation of Obesity and Associated Metabolic Alterations.Plant foods for human nutrition (Dordrecht, Netherlands) · 2025Article
- Bioactive Flavonoids in Protecting Against Endothelial Dysfunction and Atherosclerosis.Handbook of experimental pharmacology · 2025Review
- Review
- Coffee, tea, and cocoa in obesity prevention: Mechanisms of action and future prospects.Current research in food science · 2024Review
- Unraveling the Antioxidant Capacity ofAntioxidants (Basel, Switzerland) · 2023Article
- Ameliorating effect of probiotic on nonalcoholic fatty liver disease and lipolytic gene expression in rabbits.Scientific reports · 2023Article
- The role of gut microbiota in the occurrence and progression of non-alcoholic fatty liver disease.Frontiers in microbiology · 2023Article
- Intestinal flora: A new target for traditional Chinese medicine to improve lipid metabolism disorders.Frontiers in pharmacology · 2023Review
- Coordination of AMPK and YAP byInternational journal of molecular sciences · 2022Article
- Procyanidin B2 Attenuates Nicotine-Induced Hepatocyte Pyroptosis through a PPARγ-Dependent Mechanism.Nutrients · 2022Article
- Proanthocyanidins and Where to Find Them: A Meta-Analytic Approach to Investigate Their Chemistry, Biosynthesis, Distribution, and Effect on Human Health.Antioxidants (Basel, Switzerland) · 2021Review
- Grape-Seed Proanthocyanidin Extract Reverts Obesity-Related Metabolic Derangements in Aged Female Rats.Nutrients · 2021Article
- Impact of Dietary Flavanols on Microbiota, Immunity and Inflammation in Metabolic Diseases.Nutrients · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundProcyanidins have beneficial effects on metabolic syndrome and antimicrobial activity, but the mechanisms underlying these effects are unclear.
aimTo investigate the effects of procyanidin B2 (PB2) on non-alcoholic fatty liver disease and to explore the possible mechanism.
methodsThirty male New Zealand white rabbits were randomized into three groups. All of them were fed either a high-fat-cholesterol diet (HCD) or chow diet. HCD-fed rabbits were treated with vehicle or PB2 daily for 12 wk. Body weight and food intake were evaluated once a week. Serum biomarkers, such as total cholesterols, triglycerides, and aspartate transaminase, were detected. All rabbits were sacrificed and histological parameters of liver were assessed by hematoxylin and eosin-stained sections. Moreover, several lipogenic genes and gut microbiota (by 16S rRNA sequencing) were investigated to explore the possible mechanism.
resultsThe HCD group had higher body weight, liver index, serum lipid profile, insulin resistance, serum glucose, and hepatic steatosis compared to the CHOW group. PB2 treatment prevented HCD-induced increases in body weight and hypertriglyceridemia in association with triglyceride accumulation in the liver. PB2 also ameliorated low-grade inflammation, which was reflected by serum lipopolysaccharides and improved insulin resistance. In rabbit liver, PB2 prevented the upregulation of steroid response element binding protein 1c and fatty acid synthase and the downregulation of carnitine palmitoyltransferase, compared to the HCD group. Moreover, HCD led to a decrease of
conclusionOur results indicate the possible mechanism of PB2 to improve HCD-induced features of metabolic syndrome and provide a new dietary supplement.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.